METASTATIC LUNG NON-SMALL CELL CARCINOMA
Clinical trials for METASTATIC LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Light-Activated drug combo targets tough lung cancers
Disease control Not yet recruitingThis study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. The approach combines a light-activated drug (ASP-1929) that targets and kills tumor cells with an immunotherapy (cemiplimab) that boosts the immune …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 17, 2026 02:14 UTC
-
Could a cheaper, easier dose of immunotherapy work just as well?
Disease control Not yet recruitingThis study tests whether giving a lower dose of the immunotherapy drug nivolumab less often can still control advanced cancers that have spread or can't be removed surgically. The goal is to make treatment more affordable and accessible worldwide. About 50 adults with various can…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New radiation drug targets bone tumors with less marrow harm
Disease control Not yet recruitingThis early-stage trial tests a new version of a radiation drug (Sn-117m-DTPA) designed to target tumors that have spread to the bones from prostate, breast, or lung cancer. The drug delivers low-level radiation directly to bone tumors while being gentler on the bone marrow. The s…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New drug duo aims to reboot immune system against tough lung cancers
Disease control Not yet recruitingThis study is testing whether a new drug, SX-682, combined with an existing immunotherapy drug (atezolizumab), can help control advanced non-small cell lung cancer that has worsened after standard chemotherapy and immunotherapy. It aims to see if this combination can help the pat…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC